Conclusions: ECT seems to be an effective treatment for patients of TRD-SUD. Moreover the response rates are equal to treatment resistant depression cases without substance use disorder.

Disclosure of Interest: None Declared

EPP0913

Role of substance use status in determining how caregivers of patients with opioid use disorders perceive positive aspects of caregiving and burden

P. Saha*, S. Saha, A. Singh, S. Sarkar and G. S. Kaloiya
Department of Psychiatry and National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India
*Corresponding author.
doi: 10.1192/j.eurpsy.2023.1193

Introduction: Substance dependence affects an individual as well as the family and is considered as a complex biopsychosocial phenomenon. Family members can act as a social and emotional support in the treatment engagement and recovery of the patient with substance use disorder. Caregiving is a multidimensional construct. Caregiving process to an individual with substance use disorder can help in either positive or negative outcome and is often challenging. Positive aspects of caregiving has gathered some attention in mental health literature in recent past, data for the same is limited across substance use disorder.

Objectives: To determine whether substance use status is associated with differences in positive aspects of caregiving and burden among the caregivers of patients with opioid use disorders.

Methods: A cross-sectional observational study with purposive sampling was used to recruit 199 caregivers of patients with opioid use disorders. The sample was divided based upon the current substance use status of the patients. Scale for Positive Aspects of Caregiving Experience (SPACE) and Family Burden Interview Schedule (FBIS) were used to assess positive aspects of caregiving and family burden respectively

Results: The study included 199 caregivers of patients with opioid use disorder. Table 1 describes the socio-demographic profile of the patients and caregivers. Of 199 caregivers recruited, 135 (67.8%) reported that the patient was using opioids, while 64 (32.2%) reported that the patient was abstinent on treatment. The mean SPACE domain score of caregivers abstinent on treatment was highest for motivation for caregiving role (2.73 versus 1.76) followed by self-esteem and social aspect of caring (2.42 versus 1.87), caregiver satisfaction (2.41 versus 1.29) and caregiving personal gains (2.40 versus 1.45). Details of SPACE domain score and FBIS are depicted in table 2. It was seen that caregivers of patients currently abstinent on treatment experienced greater positive aspects of caregiving (SPACE mean score 128.3 versus 80.1, t = 9.383, p < 0.001), and lesser burden (FBIS mean score 13.4 versus 29.3, t = 10.419, p < 0.001). Overall the mean SPACE domain score had a negative correlation with FBIS (r = -0.57, p<0.001).

Conclusions: In our study it was found that caregivers of patients who are currently abstinent on treatment experience lower burden of care, and also experience greater positive aspects of caregiving. Clinicians should be aware of the caregiver experiences as well as they engage both patients and caregivers in the treatment process.
EPP0914
Pragmatic Clinical Trial to Improve Screening and Treatment for Opioid Use Disorder in Primary Care

R. Rossom1,2
1HealthPartners Institute, Minneapolis and 2University of Minnesota, Minneapolis
doi: 10.1192/j.eurpsy.2023.1194

Introduction: Opioid-related deaths continue to rise in the U.S. A clinical decision support (CDS) system to help primary care clinicians (PCCs) identify and treat patients with opioid use disorder (OUD) could help address this crisis.

Objectives: To implement and test an OUD-CDS system in three health systems for the diagnosis and treatment of OUD in 90 primary care clinics.

Methods: In this cluster-randomized trial, primary care clinics in three healthcare systems were randomized to receive or not receive access to an OUD-CDS system. The OUD-CDS system alerts PCCs and patients to elevated risk of OUD and supports OUD screening and treatment. It includes guidance on OUD screening and diagnosis, treatment selection, starting and maintaining patients on buprenorphine for waivered clinicians, and screening for common comorbid conditions. The primary study outcome is, of patients at high risk for OUD, the percentage receiving an OUD diagnosis within 30 days of index visit. Additional outcomes are, of patients at high risk for or with a diagnosis of OUD, (a) the percentage receiving a naloxone prescription, or (b) the percentage receiving a medication for OUD (MOUD) prescription or referral to specialty care within 30 days of an index visit, and (c) total days covered by a MOUD prescription within 90 days of an index visit.

Results: The intervention started in April 2021 and continues through December 2023, with successful implementatio and uptake. PCCs and patients in 90 clinics are included; study results are expected in 2024.

Conclusions: If effective, this OUD-CDS intervention could improve screening of at-risk patients and rates of OUD treatment for people with OUD, a significant step in decreasing the morbidity and mortality associated with OUD.

Disclosure of Interest: None Declared

Image 2:

Image 3:

EPP0915
Characterization of cannabis withdrawal symptoms and serum levels of neurotransmitters among cannabis-dependent smokers during sustained abstinence within a controlled residential environment

R. Sharma1*, S. K. Tikka2, A. R. Bhute1, P. Dhamija3 and B. K. Bastia1
1Forensic Medicine and Toxicology, AIIMS, Rishikesh, Uttarakhand; 2Psychiatry, AIIMS, Bibinagar, Telangana and 3Pharmacology, AIIMS, Rishikesh, India
*Corresponding author.
doi: 10.1192/j.eurpsy.2023.1195

Introduction: Cannabis (aka marijuana) is the most frequently consumed illicit substance worldwide, and a subset of frequent cannabis smokers (up to 30%) develop dependence. A less well-known consequence of cannabis dependence is withdrawal syn-